The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Evidence of PIK3CA and TP53 co-mutation in breast cancer identification on next-generation sequencing (NGS) of ERBB2 (HER2)-amplified residual disease following preoperative anti-HER2 therapy.
Frankie Ann Holmes
Consultant or Advisory Role - bioTheranostics
Honoraria - Genentech
Kai Wang
Employment or Leadership Position - Foundation Medicine
Stock Ownership - Foundation Medicine
Maren K. Levin
No relevant relationships to disclose
Ying Cao
No relevant relationships to disclose
Gary A. Palmer
Employment or Leadership Position - Foundation Medicine
Stock Ownership - Foundation Medicine
Norma Alonzo Palma
Employment or Leadership Position - Foundation Medicine
Stock Ownership - Foundation Medicine
Sohail Balasubramanian
Employment or Leadership Position - Foundation Medicine
Stock Ownership - Foundation Medicine
Jeffrey S. Ross
Employment or Leadership Position - Foundation Medicine
Stock Ownership - Foundation Medicine
Research Funding - Foundation Medicine
Roman Yelensky
Employment or Leadership Position - Foundation Medicine
Stock Ownership - Foundation Medicine
Lea Krekow
No relevant relationships to disclose
Kristi McIntyre
No relevant relationships to disclose
Cynthia R. C. Osborne
No relevant relationships to disclose
Joyce O'Shaughnessy
No relevant relationships to disclose